Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported

Leuk Res. 2020 Apr:91:106338. doi: 10.1016/j.leukres.2020.106338. Epub 2020 Feb 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Blood Platelets / drug effects
  • Blood Platelets / enzymology
  • Blood Platelets / pathology
  • Europe / epidemiology
  • Gene Expression
  • Health Services Needs and Demand / trends*
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase 2 / genetics
  • Janus Kinase 2 / metabolism
  • Nitriles
  • Physicians
  • Prevalence
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / epidemiology*
  • Primary Myelofibrosis / pathology
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Pyrrolidines / therapeutic use*
  • Severity of Illness Index
  • Sulfonamides / therapeutic use*
  • Surveys and Questionnaires
  • Thrombocytopenia / diagnosis
  • Thrombocytopenia / drug therapy
  • Thrombocytopenia / epidemiology*
  • Thrombocytopenia / pathology
  • United States / epidemiology

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • Pyrrolidines
  • Sulfonamides
  • fedratinib
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2